Ascelia Pharma is betting that growing worries about the safety and environmental impact of today’s common MRI contrast dyes push hospitals toward its manganese-based alternative for cancer patients with kidney problems. The upside hinges on regulators signing off and the company landing a strong commercial partner before cash runs tight.Read more
A small drugmaker is betting that a new liver-imaging product can help patients who can’t safely use today’s standard MRI contrast agents, and it could become its first real source of sales. The big questions are whether regulators sign off and whether the company can land the right hospital-market partner before better-funded rivals catch up.Read more
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
